lung

Johnson & Johnson, today announced it has entered into a definitive agreement to acquire Auris Health, a developer of robotic technologies for $3.4 billion in cash. Auris Health is a privately held developer of robotic technologies, initially focused on lung cancer, with an FDA-cleared Monarch platform currently used in bronchoscopic diagnostic and therapeutic procedures. This acquisition will accelerate Johnson & Johnson’s entry into robotics and strengthens its digital surgery
Read More